In 3T3-L1 cells stimulated using apoC-III on C57/BL6 mice with tyloxapol-induced NAFLD, aucubin hampered the development of hyperlipidemia by influencing the regulation of ApoC-III, which controls total cholesterol, triglyceride, LDL, and VLDL levels, and by activating AMPK, Nrf2, PPARα, and PPARγ pathways, leading to the activation of fatty acid oxidation [62]. The gene discussed is APOC3; the disease is metabolic dysfunction-associated steatotic liver disease.